National Cancer Institute; Notice of Closing Meeting, 60539-60540 [05-20743]

Download as PDF 60539 Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices EXHIBIT 1—Continued Number of respondents Type of respondents * Dietary Recall 3 ........................................................................................ Mail Survey ............................................................................................... Pilot Study 2: Mail Survey ............................................................................................... Main Implementation 5 A Day Customized Survey .................................................................... Total ................................................................................................... Frequency of response Average burden hours Annual hour burden 290 200 1 1 .50 .42 145 84 200 2 .42 168 4,000 1 .42 1,680 5,875 ........................ ........................ 2,467.90 *All respondents are consumer panel members. Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proposed performance of the functions of the agency, including whether the information shall have practical utility; (2) the accuracy of the estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Direct Comments to OMB: Written comments and/or suggestions regarding item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Amy Lazarus Yaroch, Ph.D., Project Officer, National Cancer Institute, NIH, EPN 4074, 6130 Executive Boulevard MSC 7335, Bethesda, Maryland 20892–7335, or call non-toll-free number 301–402– 8425, or FAX your request to 301–480– 2087, or E-mail your request, including your address, to yarocha@mail.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of this notice. VerDate Aug<31>2005 17:22 Oct 17, 2005 Jkt 208001 Dated: October 5, 2005. Rachelle Ragland-Greene, NCI OMB Clearance Liaison, National Institutes of Health. [FR Doc. 05–20756 Filed 10–17–05; 8:45 am] Dated: October 4, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–20748 Filed 10–17–05; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health Office of Biotechnology Activities, Office of the Director; Notice of Meeting National Cancer Institute; Amended Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a special meeting of the National Science Advisory Board for Biosecurity (NSABB) that was held by teleconference on September 29, 2005. The Secretary determined that advance notice was not possible, and that the meeting had to be closed to the public in accordance with the provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. Under authority 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established NSABB to provide advice, guidance and leadership regarding Federal oversight of dual-use research, defined as biological research with legitimate scientific purposes that could be misused to pose a biological threat to public health and/or national security. Name of Committee: National Science Advisory Board for Biosecurity. Date: September 29, 2005. Closed: 10 a.m. to 12 p.m. Agenda: To review confidential information. Place: 6705 Rockledge Drive, Bethesda, Maryland, (Telephone Conference Call). Contact Person: Allison Chamberlain, NSABB Program Assistant, 6705 Rockledge Drive, Bethesda, Maryland 20892, (301) 496– 9838. PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 Notice is hereby given of a change in the meeting of the President’s Cancer Panel, October 24, 2005, 8 a.m. to October 24, 2005, 5 p.m., Hotel Washington, Pennsylvania Ave at 15th Street, NW., Washington, DC, 20004 which was published in the Federal Register on September 27, 2005, 70 FR 56477. This meeting is amended to change the end time of the open session from 5 p.m. to 4 p.m. on October 24, 2005 and the date and time of the closed session from 1 p.m.–4 p.m. on October 25, 2005 to 4:15 p.m.–6:15 p.m. on October 24, 2005. The meeting is partially Closed to the public. Dated: October 5, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–20742 Filed 10–17–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closing Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. E:\FR\FM\18OCN1.SGM 18OCN1 60540 Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, RFA: CA06–002 and CA06–005 Innovative Technologies for Molecular Analysis of Cancer. Date: November 9–10, 2005. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Sherwood Githens, PhD, Scientific Review Administrator, Special Review and Logistics Branch, National Cancer Institute, Division of Extramural Activities, 6116 Executive Blvd. Room 8053, Bethesda, MD 20892, 301/435–1822, githenss@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Center Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: October 5, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–20743 Filed 10–17–05; 8:45 am] BILLING CODE 4140–01–M Name of Committee: President’s Cancer Panel. Date: October 25, 2005. Time: 8 a.m. to 5 p.m. Agenda: Assessing Progress, Advancing Change: Challenges in Translating Research. Place: Hotel Washington, Pennsylvania Ave at 15th Street, NW., Washington, DC 20004. Contact Person: Abby B. Sandler, PhD, Executive Secretary, Acting Chief, Institute Review Office, Office of the Director, 6116 Executive Blvd., Suite 212, MSC 8349, National Cancer Institute, NIH, Bethesda, MD 20892–8349, (301) 451–9399, sandlera@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement of the Contact Person listed on this notice. This statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// deafino.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support, 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Name of Committee: National Cancer Institute Special Emphasis Panel, Cancer Sample Preparation/Cancer Detection. Date: November 2, 2005. Time: 9 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Thomas M. Vollberg, PhD, Scientific Review Administrator, Special Review And Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 7142, Bethesda, MD 20892, 301/594–9584, volbert@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: October 5, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–20744 Filed 10–17–05; 8:45 am] National Institutes of Health BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute; Notice of Closed Meeting National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Cancer Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the President’s Cancer Panel. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. VerDate Aug<31>2005 17:22 Oct 17, 2005 Jkt 208001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Dated: October 4, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–20749 Filed 10–17–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, ‘‘In Vivo Cellular and Molecular Imaging Centers (ICMICS)’’. Date: November 3, 2005. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Marriott—University of Maryland, The Inn and Conference Center, 3501 University Boulevard East, Adelphi, MD 20783. E:\FR\FM\18OCN1.SGM 18OCN1

Agencies

[Federal Register Volume 70, Number 200 (Tuesday, October 18, 2005)]
[Notices]
[Pages 60539-60540]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-20743]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closing Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.

[[Page 60540]]

    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, RFA: CA06-002 and CA06-005 Innovative Technologies for 
Molecular Analysis of Cancer.
    Date: November 9-10, 2005.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, 
Bethesda, MD 20817.
    Contact Person: Sherwood Githens, PhD, Scientific Review 
Administrator, Special Review and Logistics Branch, National Cancer 
Institute, Division of Extramural Activities, 6116 Executive Blvd. 
Room 8053, Bethesda, MD 20892, 301/435-1822, githenss@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Center Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: October 5, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-20743 Filed 10-17-05; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.